Trametinib and Dabrafenib Therapy. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Trametinib and Dabrafenib Therapy, 2021, version number 4, NCCP National SACT Regimen, NCCP, viewed on 26/03/2026, https://healthservice.hse.ie/documents/6732/415_v4_Trametinib_and_DabrafenibTherapy.pdf

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. 2
Adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection. 2

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
HSE (2) BRAF p.V600E Melanoma Dabrafenib, Trametinib
HSE (2) BRAF p.V600K Melanoma Dabrafenib, Trametinib